GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Univo Pharmaceuticals Ltd (XTAE:UNVO-M) » Definitions » Retained Earnings

Univo Pharmaceuticals (XTAE:UNVO-M) Retained Earnings : ₪-100.92 Mil (As of Jun. 2022)


View and export this data going back to 2011. Start your Free Trial

What is Univo Pharmaceuticals Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Univo Pharmaceuticals's retained earnings for the quarter that ended in Jun. 2022 was ₪-100.92 Mil.

Univo Pharmaceuticals's quarterly retained earnings declined from Dec. 2021 (₪-75.17 Mil) to Mar. 2022 (₪-79.91 Mil) and declined from Mar. 2022 (₪-79.91 Mil) to Jun. 2022 (₪-100.92 Mil).

Univo Pharmaceuticals's annual retained earnings increased from Dec. 2019 (₪-69.09 Mil) to Dec. 2020 (₪-68.90 Mil) but then declined from Dec. 2020 (₪-68.90 Mil) to Dec. 2021 (₪-75.17 Mil).


Univo Pharmaceuticals Retained Earnings Historical Data

The historical data trend for Univo Pharmaceuticals's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Univo Pharmaceuticals Retained Earnings Chart

Univo Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Retained Earnings
Get a 7-Day Free Trial Premium Member Only -0.49 -57.30 -69.09 -68.90 -75.17

Univo Pharmaceuticals Quarterly Data
Dec14 Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -68.72 -71.41 -75.17 -79.91 -100.92

Univo Pharmaceuticals Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Univo Pharmaceuticals  (XTAE:UNVO-M) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Univo Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Harshar 20, Ashkelon, ISR, 7878329
Univo Pharmaceuticals Ltd is engaged in designing & developing drugs for the treatment of brain disorders. The company provides cannabis-based products for distribution and export to the international markets.

Univo Pharmaceuticals Headlines

No Headlines